Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A predictive model for treatment failure in CLL/SLL patients receiving BTK inhibitor: A multi-center retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXinting Hu

Discussion

Loading...

Member takes

Overview

Retrospective analysis identified predictors of therapy failure in CLL/SLL patients, suggesting risk factors for tailored treatment.

Key Points

  • This study aims to develop a predictive model for treatment failure in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma receiving BTK inhibitors.
  • Conducted a retrospective analysis of CLL/SLL patients treated with ibrutinib and other BTK inhibitors.
  • Patients were stratified into development and validation sets using block randomization.
  • Logistic regression analysis identified covariates associated with BTKi therapy failure.
  • Out of 139 patients, 61.87% were male with a median age of 65.
  • The model revealed four independent predictors of treatment failure: Lipoprotein (a) > 0.3g/L, High-risk FISH, Complex karyotype.
  • The model showed favorable discrimination with an area under the curve of 0.725 in the training set and 0.714 in the validation set.

Cite This Study

Xinting Hu (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d214https://doi.org/10.1182/blood-2025-7423
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China2025
  2. 2Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025
  3. 3Systematic molecular profiling to identify determinants of response to ibrutinib2025
  4. 4Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  5. 5Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025